SEER Inquiry System - Question 20250030 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 12/17/2025 2:46 PM

Question 20250030

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

#1: SEER*Rx. Octreotide Acetate

#2: NCCN Guidelines. Central Nervous System Cancers, 2025; Neuroendocrine and Adrenal Tumors, 2025

Question:

First Course of Therapy/Hormone Therapy--Meningioma: Should Sandostatin be coded as treatment for a Grade 1 meningioma? Patient had surgery and was somatostatin receptor 2 (SSTR2) positive by immunohistochemistry.

Discussion:

Answer:

Code Sandostatin (octreotide acetate) as hormonal therapy when given including:

· SSTR 2 positive meningioma (NCCN, 2025: smaller studies support the use of targeted therapy including somatostatin)

· Neuroendocrine tumor (NET) (NCCN, 2025: Tumor control: antitumor effect is supported by studies for well-differentiated G1/G2 gastro-entero-pancreatic NET. In lung/thymic NET, somatostatin analogues may be considered if metastatic or SSTR positive).

The SEER*Rx entry for Octreotide Acetate was updated as studies showed somatostatin analogs may shrink tumors or inhibit further growth.

Cancer Site Category:

Brain and CNS

Data Item Category:

Hormone Therapy

Other Category:

First Course of Therapy

Year:

2025